Amgen Inc. AMGN

414.61 8.57 2.11% as of 25 Sep
Market cap
$219.1B
P/E
25.6×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Amgen Inc. (AMGN) EV/Sales

As of 25 September 2026, Amgen Inc. (AMGN) trades at a EV/Sales of 7.0×. Over the past ten years it has ranged from 4.4× (November 2016) to 8.1× (February 2024); the current reading is higher than 93% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 6.0× 7.13%
FY2024 5.6× (25.44%)
FY2023 7.5× 16.59%
FY2022 6.5× 9.56%
FY2021 5.9× (4.36%)
FY2020 6.2× (13.49%)
FY2019 7.1× 27.22%
FY2018 5.6× 4.23%
FY2017 5.4× 13.32%
FY2016 4.8× (16.37%)

Quarterly

Period EV/Sales Change
Jun 2026 6.3× (0.81%)
Mar 2026 6.3× 4.85%
Dec 2025 6.0× 10.10%
Sep 2025 5.5× (3.63%)
42 more quarters

Against its own ten years

Low 4.4× High 8.1×
Ten-year median 6.0×
Current reading's percentile 93

EV/Sales against peers

Company EV/Sales
BMY Bristol Myers Squibb Company compare 3.3×
PFE Pfizer Inc. compare 3.4×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.6×
NVS Novartis AG compare 5.6×
MRK Merck & Co., Inc. compare 6.2×
GILD Gilead Sciences, Inc. compare 6.9×
AMGN Amgen Inc. 7.0×
ABBV AbbVie Inc. compare 8.3×
Drug Manufacturers General industry median 4.0×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on AMGN